Filing Flows

Filing Flows › Companies › Avita Medical › Cash flow

Avita Medical cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$821K in Q3 2026 · −$19.3M over twelve months

Operating cash flow−$710K
Capital spending−$111K
Free cash flow−$821K
Cash conversion cycle23 days

Analysis

In Q3 2026, Avita Medical generated −$710K of operating cash flow and spent $111K on capital projects, leaving free cash flow of −$821K. That is $5.3M more than in Q3 2025 (−$6.2M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$19.7M; the largest uses were operating cash flow ($19.7M); besides operations, cash came from other investing ($7.4M), other financing ($6.8M); the cash balance fell by $4.9M.

Operating cash flow was −$710K against net income of −$6.2M. The largest differences: employee-related liabilities +$2.7M, stock-based pay +$1.7M, payables −$1.6M.

Its cash conversion cycle was 23 days (receivables 36 + inventory 111 − payables 124).

Free cash flow

Avita Medical: free cash flow by quarterAvita Medical: free cash flow by quarter−$9.7MQ4 2024−$10.5MQ1 2025−$10.8MQ2 2025−$6.2MQ3 2025−$4.8MQ4 2025−$10.1MQ1 2026−$3.6MQ2 2026−$821KQ3 2026
Operating cash flow less capital spending.
Avita Medical: operating cash flow against capital spendingAvita Medical: operating cash flow against capital spendingOperating cash flowCapital spending−$8.0M$1.6MQ4 2024−$10.3M$221KQ1 2025−$10.2M$524KQ2 2025−$5.2M$934KQ3 2025−$5.4M−$674KQ4 2025−$10.1M$19KQ1 2026−$3.5M$108KQ2 2026−$710K$111KQ3 2026
Latest (Q3 2026): Operating cash flow −$710K, Capital spending $111K.

Capital allocation, year by year

Avita Medical: where the cash came from (up) and went (down), by fiscal yearAvita Medical: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingFY2022: Operating cash flow −$19.1MFY2022: Shares issued $900KFY2022: Capital spending −$452K$900KFY2022FY2023: Operating cash flow −$38.0MFY2023: Net borrowing $38.8MFY2023: Shares issued $957KFY2023: Capital spending −$1.4M$39.7MFY2023FY2024: Operating cash flow −$48.9MFY2024: Shares issued $2.1MFY2024: Capital spending −$9.2M$2.1MFY2024FY2025: Operating cash flow −$31.2MFY2025: Shares issued $15.2MFY2025: Capital spending −$1.0M$15.2MFY2025
Over these 4 years operating cash flow totalled −$137M; the largest uses were operating cash flow ($137M) and capital spending ($12.0M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$10.5M
Debt$45.5M
Net debt$35.0M
Cash runway7 months

Avita Medical is burning cash: its operations consume cash, a free cash flow of −$19.3M a year at the current rate against $10.5M of cash and investments: a runway of about 7 months before any new financing.

Where the cash came from and went

Avita Medical: sources (+) and uses (−) of cash, Q3 2026Avita Medical: sources (+) and uses (−) of cash, Q3 2026Other investing$2.0MCash drawn (+) / kept (−)−$1.4MOperating cash flow−$710KShares issued$182KCapital spending−$111K
Avita Medical: sources (+) and uses (−) of cash, TTM to Q3 2026Avita Medical: sources (+) and uses (−) of cash, TTM to Q3 2026Operating cash flow−$19.7MOther investing$7.4MOther financing$6.8MCash drawn (+) / kept (−)$4.9MCapital spending$436KShares issued$183KNot reconciled$5K

From profit to cash

Avita Medical: net income to operating cash flow, Q3 2026Avita Medical: net income to operating cash flow, Q3 2026Net income−$6.2MDepreciation & amortization$592KStock-based pay$1.7MGains on disposals$93KInventory$363KPayables−$1.6MEmployee-related liabilities$2.7MDeferred revenue−$8KPrepaid and other assets$74KOther liabilities−$660KOperating cash flow−$710K
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q3 20263611112423
Q2 20264113215816
Q1 2026441672074
Q4 2025471972387
Q3 20255521322246
Q2 20255120920950
Q1 20255124923862
Q4 202455272211116

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$710K−$111K—$182K−$1.4M−$821K
Q2 2026−$3.5M−$108K——−$830K−$3.6M
Q1 2026−$10.1M−$19K$49.1M—$1.9M−$10.1M
Q4 2025−$5.4M$674K—$1K$5.2M−$4.8M
Q3 2025−$5.2M−$934K—$32K−$3.2M−$6.2M
Q2 2025−$10.2M−$524K—$11K$2.7M−$10.8M
Q1 2025−$10.3M−$221K—$363K−$820K−$10.5M
Q4 2024−$8.0M−$1.6M—$434K$4.6M−$9.7M

Avita Medical: income statement and cash flow

Avita Medical, Q3 2026: revenue $26.1M (+53% year over year), operating margin -10.1%. The chart follows the revenue to costs, profit and cash.

Avita Medical: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.